12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brintellix vortioxetine regulatory update

FDA approved an NDA from Takeda for Brintellix vortioxetine to treat major depressive disorder (MDD). Takeda and partner H. Lundbeck plan to...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >